Middle East Oncology Based Molecular Diagnostics Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

The Middle East & Africa oncology molecular diagnostics market covers technologies including polymerase chain reaction (PCR), in-situ hybridization, next-generation sequencing (NGS), and mass spectrometry used to detect genetic mutations and biomarkers in cancer patients. The regional market was valued at approximately $6.18 billion in 2025 and is projected to grow steadily as healthcare systems invest in advanced diagnostic capacity. Rising cancer prevalence, an expanding middle-class population with greater healthcare access, and regional commitments to precision medicine underpin market expansion.

• •Market valued at ~$6.18 billion in 2025 with 11.32% annual growth trajectory
• •Encompasses NGS, PCR, FISH, and mass spectrometry platforms for oncology applications
• •Represents a growing portion of the global molecular diagnostics sector exceeding $25.2 billion

A major driver is the projected sharp increase in cancer cases across sub-Saharan Africa and the broader region through 2025-2030, creating substantial unmet diagnostic demand. Government-backed initiatives such as the UAE National Genomics Strategy are accelerating the adoption of precision medicine frameworks and genomic testing infrastructure. Additionally, growing evidence that molecular profiling improves treatment outcomes and cost-effectiveness, such as demonstrated in breast cancer genetic profiling research in Egypt, is encouraging clinical adoption and reimbursement support.

• •Rising cancer incidence across Africa and the Middle East creating urgent diagnostic demand through 2030
• •Government-led precision medicine programs including the UAE National Genomics Strategy
• •Demonstrated cost-effectiveness of molecular profiling driving payer and provider acceptance

The market spans diverse geographies with Gulf Cooperation Council countries such as the UAE leading in infrastructure investment and genomic program adoption. Sub-Saharan Africa represents an emerging opportunity driven by increasing urbanization, expanding pathology and molecular laboratory networks in major cities, and growing oncology research activity. Test categories span companion diagnostics, screening assays, prognostic tests, and NGS-based multi-gene panels, with breast, lung, and colorectal cancers representing the highest clinical demand.

• •GCC nations lead adoption; sub-Saharan Africa emerging with expanding urban laboratory networks
• •Breast, lung, and colorectal cancers drive highest molecular testing demand
• •Companion diagnostics, NGS panels, and screening assays are key product categories

What are the recent trends and outlook?

AI-powered diagnostic tools, wearable health monitoring devices, and integrated multi-omics approaches are beginning to influence the precision oncology landscape in the region. The market is expected to sustain double-digit growth through the decade as NGS costs decline, genomic literacy among clinicians increases, and national health systems prioritize cancer genomics in strategic planning. Continued expansion of laboratory-accredited molecular testing facilities and growing participation in international oncology genomics research consortia will further shape regional development through 2030.

• •AI-enhanced diagnostics and multi-omics integration emerging as next-wave technologies in regional oncology
• •NGS costs declining, supporting broader access to comprehensive genomic profiling
• •Regional market expected to sustain strong growth trajectory aligned with global precision medicine expansion through 2030